Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1887-1901

  Bottomley, Julia M ^a   Auland, Merran E ^a   Morais, Jeremy ^b   Boyd, Gordon ^b   Douglas, W Stewart ^c  

^a Amygdala Ltd   (United Kingdom)

^b Leo Pharmaceuticals   (United Kingdom)

^c MONKLANDS HOSPITAL   (United Kingdom)

Author keywords

Betamethasone dipropionate; Calcipotriol; Clinical trial; Cost; Cost effectiveness; Psoriasis; Quality of life; Steroids; Utility

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; DITHRANOL; STEROID; TACALCITOL; TOPICAL AGENT;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; PATIENT COMPLIANCE; PHOTOTHERAPY; PRIMARY MEDICAL CARE; PSORIASIS VULGARIS; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; HUMANS; PSORIASIS; QUALITY-ADJUSTED LIFE YEARS; SCOTLAND; STATE MEDICINE; TREATMENT OUTCOME;

EID: 34548133079     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210688     Document Type: Article

References (59)

1. Rees J. The characteristics of an enigmatic disease. Psoriasis Pract 2002;1:1-3
2. Berth-Jones J. Psoriasis. Medicine 2005;33:50-55
3. Lebwohl M. Psoriasis. Lancet 2003;361:1197-204
4. Henseler T, Christophers E. Psoriasis of early and late onset: characterisation of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6
5. Smith AE, Kassab J, Payne C, et al. Bimodality in age of onset of psoriasis, in both patients and their relatives. Dermatology 1993;186:181-6
6. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42:796-802
7. Rapp S, Feldman S, Exum M, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
8. Zachariare R, Zachariare H, Blomqvist K, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002;146:1006-16
9. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1-18
10. Julian CG. Dermatology in general practice. Br J Dermatol 1999;141:518-20
11. Cork M. Economic considerations in the treatment of psoriasis. Dermatol Pract 1993;1:16-20
12. Harris DW, Benton EC, Hunter JA. The changing face of dermatology outpatient referrals in the south-east of Scotland. Br J Dermatol 1990;123:745-50
13. CompuFile Ltd. DIN-LINK report: Body and scalp psoriasis February, 2005
14. Dawe, R Wainwright NJ, Cameron H, et al. Narrow band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 1998;138:833-9
15. Summary Report of Expert Findings, 21 March 2005. Data on file 16.
16. Dermatology - Psoriasis Patient Pathway April 2005 http://www.pathways. scot.nhs.uk/Dermatology/Dermatology%20Psoriasis%2023Sep05.htm [accessed on 20 October 2006]
17. Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998;139:649-54
18. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268-9
19. Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomised study. Br J Dermatol 1998;138:254-8
20. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol 1997;37:S55-8
21. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-5
22. Guenther L, Cambazard F, van de Kerkhof PCM, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomised, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-23
23. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54
24. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate (Daivobet) is an effective once daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-93
25. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004;150:1167-73
26. Ortonne J-P, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004;209:308-13
27. Van de Kerkhof PCM. A fixed combination of calcipotriol/betamethasone dipropionate improves quality of life. Abstract presented at EADV (European Academy of Dermatology and Venereology) Prague, 2002
28. Nørregaard J, Lowson D. The cost utility of calcipotriol/ betamethasone (Dovobet®) ointment in the treatment of psoriasis vulgaris in the United Kingdom (abstract). Value Health 2003;6:785
29. Kragballe K, van de Kerkhof PCM. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006;20:39-44
30. Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British Health Service. JAMA 2005;294:2618-22
31. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52
32. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgements. BMJ 2004;329:224-7
33. Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998;38:1010-11
34. Gordon K, Feldman S, Koo J, et al. Definitions of measures of effect duration for psoriasis treatments. Psoriasis Forum 2002;8:1-3
35. Anstey AV, Kragballe K. A retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 2006;45:970-5
36. Song F, Altman D, Glenny A-M, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472-6
37. Data on file. (Clinical Study Report MC 9302 INT: 1997)
38. Mason J, et al. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146:351-64
39. Griffiths CEM, Camp RDR, Barker JNWN. Psoriasis. In: Burns DA, Breathnach SM, Cox NH, Griffiths CEM, eds. Rook's Textbook of Dermatology, 7th edn, Vol 2. Oxford: Blackwell Publishing, 2004:35.1-35.69
40. www.show.scot.nhs.uk/waiting/
41. Marchetti A, LaPensee K, An P. A pharmacoeconomic analysis of topical therapies for patients with mild to moderate stable plaque psoriasis: A US study. Clin Ther 1998;20:851-69
42. Monthly Index of Medical Specialities February 2007
43. Curtis L, Netten A. Unit Costs of Health & Social Care 2006. http://www.pssru.ac.uk/uc/uc2006contents.htm (Accessed 7 March 2007)
44. Scodand Health Service Costs 2006. Specialty Group Costs - Outpatients. Consultant Clinics. Report 044. Section 6B. Outpatients (Dermatology). See http://www.isdscotland.org/isd/information.jsp?pContentID=3583&p_applic= CCC&p_service=Content.show& [Accessed on 15 March 2007]
45. Scotland Health Service Costs 2006. Specialty Group Costs - Outpatient Nurse Led Clinics. Report 045. Outpatients (Dermatology). See http://www.isdscotland.org/isd/information.jsp?pContentID=3583&p_applic= CCC&p_service=Content.show& [Accessed on 15 March 2007]
46. Kind P. The EuroQol instrument: an index of health-related quality of life In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996
47. Oh PI, Gupta AK, Einarson TR, et al. Calcipotriol in the treatment of psoriasis of limited severity: pharmacoeconomic evaluation. J Cutan Med Surg 1997;2:7-15
48. Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-75
49. Jacobson CC, Kimball AB. Rethinking the psoriasis area and severity index: the impact of area should be increased. Br J Dermatol 2004;151:381-7
50. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9(26):1-134
51. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900
52. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
53. Guide to the methods of technology appraisal review process and timelines. 16 April 2007;National Institute for Health and Clinical Excellence. See http://www.nice.org.uk [Accessed 16 April 2007]
54. Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52 week, randomized, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet®/Dovobet®/Taclonex®) in the treatment of psoriasis vulgaris. Dermatology 2006;213:319-26
55. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet®/Dovobet®/Taclonex®) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-60
56. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46):1-252
57. ACD Psoriasis - efalizumab and etanercept [accessed on www. nice.org.uk on 6 September 2005]
58. Etanercept and efalizumab for the treatment of adults with psoriasis. NICE Technology Appraisal Guidance 103. July 2006. Accessed on www.nice.org.uk on 15 March 2007]
59. Peeters P, Ortonne J-P, Sitbon R, et al. Cost effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology 2005;211:139-45